CLLS vs. ANNX, SEPN, CMPS, DSGN, AVIR, CADL, CRVS, IMMP, MBX, and SLRN
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Annexon (ANNX), Septerna (SEPN), COMPASS Pathways (CMPS), Design Therapeutics (DSGN), Atea Pharmaceuticals (AVIR), Candel Therapeutics (CADL), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), MBX Biosciences (MBX), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical products" industry.
Cellectis vs.
Cellectis (NASDAQ:CLLS) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, community ranking, dividends, risk, institutional ownership and earnings.
Cellectis received 356 more outperform votes than Annexon when rated by MarketBeat users. However, 77.46% of users gave Annexon an outperform vote while only 65.03% of users gave Cellectis an outperform vote.
Cellectis has a beta of 3.27, meaning that its stock price is 227% more volatile than the S&P 500. Comparatively, Annexon has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500.
Annexon has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Annexon's return on equity of -38.99% beat Cellectis' return on equity.
In the previous week, Annexon had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for Annexon and 1 mentions for Cellectis. Annexon's average media sentiment score of 0.94 beat Cellectis' score of 0.32 indicating that Annexon is being referred to more favorably in the news media.
63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Comparatively, 12.7% of Annexon shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cellectis has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.
Cellectis currently has a consensus price target of $7.00, suggesting a potential upside of 438.46%. Annexon has a consensus price target of $17.25, suggesting a potential upside of 670.09%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Cellectis.
Summary
Cellectis beats Annexon on 9 of the 16 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
This page (NASDAQ:CLLS) was last updated on 3/28/2025 by MarketBeat.com Staff
